The highest quality primary antibodies are available for use in your Alzheimerís/Parkinsonís disease research. We offer over 35 antibodies in the Alzheimerís/Parkinsonís disease research area including antibodies against tau, alpha synuclein, beta synuclein, gamma synuclein, APP and parkin. Biosensis antibodies can be used in many applications including ELISA, western blot and immunohistochemistry (IHC). Recently published work by Song et al (2009) and Huang et al (2008) used the Biosensis parkin antibody R-114-100. Tinsley and colleagues (2010) published their new ELISA protocol using the Biosensis alpha synuclein antibody R-075-100.
Alzheimerís Disease (AD) is a devastating neurological disease that affects more than 37 million people worldwide. The presence and accumulation of beta-amyloid in the brain and the self-assembly of hyper-phosphorylated tau protein tangles are thought to contribute to the development and pathogenesis of AD.
Parkinsonís Disease (PD) is a degenerative disease of the central nervous system resulting in the loss of dopamine-producing cells in the brain. Leucine-rich repeat kinase 2 or LRRK2 (also now classified as PARK8) became of great interest in 2004 when it was identified as the second autosomal dominant PD gene involving a toxic gain of function. Biosensis was the first company to offer high quality sheep and rabbit antibodies against LRRK2.